Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. H.J. (Hiddo) Lambers Heerspink

Publicaties

Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial

Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes

Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials

Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease

Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps

Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study

Impact of age on the predictive value of NT-proBNP in patients with diabetes mellitus stabilised after an acute coronary syndrome

Impact of Using the Race-Free 2021 CKD-EPI Creatinine Equation on Treatment Effects on GFR-Based End Points in Clinical Trials

Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD

Lees meer

Pers/media

Zibotentan, Dapagliflozin Combo Further Reduces Albuminuria in CKD

New Hope for Treating Chronic Kidney Disease in Type 1 Diabetes

First-in-class treatment delivers major advance for incurable kidney disease

First-in-Class Treatment Brings Major Breakthrough for Incurable Kidney Disease

First-in-class treatment delivers major advance for incurable kidney disease

Diabetes drug can slow kidney function decline, study finds

La dapagliflozina no reduce los riesgos en los pacientes hospitalizados con COVID-19

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

Lees meer